Search results
Results from the WOW.Com Content Network
Compared to THC, which is a partial agonist at CB 1 receptors, JWH-018, and many synthetic cannabinoids, are full agonists. JWH-018 may cause intense anxiety, agitation, and in rare cases, has been assumed to have been the cause of seizures and convulsions. JWH-018 and analogs of it may present serious dangers to the user when used to excess. [22]
Also, most synthetic cannabinoids are agonists of both cannabinoid receptors, CB 1 and CB 2, like THC; however, they often have greater binding affinity and therefore greater potency than THC, as seen in table two. Due to the greater potency, the standard doses of many synthetic cannabinoids may be less than 1 mg. [50]
EAM-2201 (4'-ethyl-AM-2201, 5"-fluoro-JWH-210, SGT-14) is a drug that presumably acts as a potent agonist for the cannabinoid receptors. [2] It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in July 2012 as an ingredient in synthetic cannabis smoking blends [3] Like the closely related MAM-2201 which had been first ...
Synthetic cannabinoids act as Synthetic Cannabinoid Receptor Agonists (SCRA) [10] by binding to cannabinoid receptors CB 1 and CB 2. Its binding towards CB 1 receptor will lead to receptor phosphorylation that recruits β-arrestin 1 and β-arrestin 2, resulting in a loss of responsiveness and internalization (endocytosis of molecules by the cell).
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB 1 and CB 2 with EC 50 values of 98 nM and 83 nM ...
AM-679 (part of the AM cannabinoid series) is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a K i of 13.5 nM at CB 1 and 49.5 nM at CB 2. [1]
AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a K i of 1.0 nM at CB 1 and 2.6 nM at CB 2. [6] The 4-methyl functional analog MAM-2201 probably has similar affinities. [original research?] AM-2201 has an EC 50 of 38 nM for human CB 1 receptors, and 58 nM for human CB 2 receptors. [7]
The state of Louisiana banned 5F-AMB through an emergency rule after it was detected in a synthetic cannabinoids product called "Kali Berry 2" on 3 June 2014. [14] 5F-AMB is controlled by the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore as of May 2015. [15] 5F-AMB was also scheduled in Japan on July 25, 2014. [16]